Group items matching

in title, tags, annotations or url

A diet supplemented with vitamin d can help support healthy weight loss and reduce fat percentage, a new clinical study revealed. A trial was conducted over a three-month period with 125 overweight and obese Southeastern European Caucasians with vitamin d deficiency or insufficiency. Participants were prescribed vitamin d3 3000 IU/d oral spray supplementation, or a placebo, alongside a calorie-restricted diet programme of 600 kcal less than the total energy expenditure of each individual. The report stated that the group who were prescribed vitamin d witnessed significant improvements in serum 25(OH)d level and a greater reduction in body weight, BMI, and fat percentage in all individuals within this group. The study supported by BetterYou found that with the prevalence of low vitamin d becoming a serious global health problem in all ages, even in areas with natural sun exposure throughout the year, the study shines a light on the importance of vitamin d supplementation.

according to recent research vitamin d fortification is necessary, as there is a widespread vitamin d deficiency in our population. the best way to get enough of this nutrient is by supplementing it with high quality supplements. there are multiple benefits of doing so – from bone health and muscle strength to improved immune function.

according to recent research vitamin d fortification is necessary, as there is a widespread vitamin d deficiency in our population. the best way to get enough of this nutrient is by supplementing it with high quality supplements. there are multiple benefits of doing so – from bone health and muscle strength to improved immune function.

Prince Charles formally opened a new 1 billion pound AstraZeneca research and development (R&d) facility in Cambridge on Tuesday (November 23), as the company aims to fuel the growth of its drug pipeline. AstraZeneca has supplied two billion doses of its Covid-19 vaccine, developed at Oxford University, and is also looking to bring a preventative antibody cocktail against Covid-19 to market. Prince Charles, son of Queen Elizabeth and heir to the throne, saw an exhibit on the pandemic and a demonstration of how augmented reality headsets can help with lab work, before hearing about the company's net-zero targets. "The last two years have been some of the most difficult of a generation," Prince Charles said in a speech.

The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&d investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GdP over 30 years, owing to increased R&d investment £16.3 billion additional annual GdP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

Johnson & Johnson has made it to the list of top 10 most innovative companies in the world released by FOREX.com. The US-based pharmaceutical company is the fourth most innovative company, scoring 8.23/10 in the innovation index. Johnson & Johnson is the only pharmaceutical company making it to top 10 list, which makes it the world's most innovative pharmaceutical company in 2023. The ranking is based on many factors such as the number of US-registered patents in 2022, the number of R&d expenses over the last 12 consecutive months and their last reported intangible assets. The health giant spent £37.16 billion on intangible assets (the second highest after Apple), £11.87 billion on R&d last year and registered 1,377 patents last year.

Leo Pharma, one of the leaders in medical dermatology, has appointed Kasper Künzel as Interim Vice President and General Manager for its UK and Ireland business. Kasper is an established leader within Leo Pharma, having previously been Vice President, IPO Preparedness Office, at Leo Pharma in denmark. Kasper brings over 17 years of pharmaceutical experience, previously taking on local and global leadership positions across Leo Pharma in functions including R&d, Finance and Commercial. Having first joined Leo Pharma in denmark in a financial function, his previous roles include General Manager in South Korea, Vice President of Corporate Transformation, and director of R&d Business Finance He commented: "I am delighted to join the Leo Pharma UK and Ireland team and continue to build on the company's strong heritage in these markets. The UK and Ireland team are committed to the Leo Pharma values as a leader in medical dermatology, and I'm looking forward to all we can achieve together this year.

A group of 21 community pharmacies in the Midlands and Yorkshire will have a new name - Pickfords Pharmacy. The group has been created by combining three independent pharmacy businesses which traded as Mr Pickford's, McGills Pharmacy and d&R Sharp. All pharmacies in the new group will be rebranded over the coming months, with a series of launch events planned by local teams. Speaking after the unveiling of the first branch to receive new signage in Hexthorpe doncaster, Mimi Lau, Pickfords Pharmacy's chief operating officer, said: "This is a turning point for the group, with all our pharmacies operating under one name with a consistent, contemporary brand. "Initial reaction has been fantastic and very soon the name Pickfords Pharmacy will be widely recognised for the great service we deliver to customers and patients every day." Speaking of the consolidation, Nick Yarrow, the newly appointed group chief executive officer, commented: "Since the enlarged group came together last year, we have been striving to ensure that the best elements of each business have been retained for the benefit of our customers and team members. "This is part of our journey to be more than just a pharmacy - we want to be a trusted source of healthcare services at the heart of each one of the communities we serve".

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&d) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

Here we bring some exciting news for McDonalD's lovers in North InDia! The McDonalD's connoisseurs have faceD a lot of Disappointment in recent times when all the outlets were shut Down. But now no more Disappointment! We got some silver lining with a pleasant twiston the Dark clouDs. McDonalD's islaunchingMcCafé in Delhi, to aDD to the Delight of 'Mc D fans'!

It is essential for your health to understand high cholesterol symptoms and tips to manage. It becomes more vital when you are above 40. First of all, let's try to understand what is Cholesterol? It is a fat-like substance that is produced by the liver naturally. It has many functions in our body like producing specific hormones, new cell membranes, and Vitamin d.

Global pharmaceutical and biotechnology company AstraZeneca has signed an agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against cancer proteins. The collaboration, announced today (January 13), will focus on a class of proteins called transcription factors, which can regulate important cellular processes including cell growth and survival. Many transcription factors have been identified earlier, but were considered 'undruggable' using conventional drug discovery approaches, the company said in a statement. Susan Galbraith, executive vice president, Oncology R&d, AstraZeneca, said: "Unlocking potentially transformative biology is pivotal for delivering the next wave of cancer treatments. "Scorpion's innovative platform is a strong strategic fit as we explore a range of new modalities across our broad drug discovery toolbox with promise to disrupt the activity of these highly-validated cancer targets."

The Hyderabad Police are actively searching for UK-based pharmacist M. Ajith Kumar, who is suspected of involvement in a plot to poison his estranged wife's family in Hyderabad by contaminating their spices with arsenic. While the accused allegedly succeeded in fatally poisoning his mother-in-law through a slow method, timely arsenic testing saved the lives of others. In late June, a newlywed woman in her 30s visited a Guntur-based doctor, complaining of intense burning, tingling, and numbness in her hands and feet. The neurologist's keen observation foiled the alleged sinister plot of Ajith Kumar, suspected of using his chemical expertise to harm his wife and her family. Presently, the police are actively searching for M. Ajith Kumar, who is currently in London, in connection with the murder plot. Furthermore, the Hyderabad police have apprehended six individuals from the city who were complicit in his nefarious scheme. The investigation gathered key information from arrested suspects, including d. Vinod Kumar, a UK-based IT professional from Andhra Pradesh. Vinod Kumar's involvement in UK software projects provided by Ajith Kumar generated a substantial monthly income, leading him to assist Ajith in his plot against his estranged wife's family.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&d Partnership (GARdP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

Winter is imminent and with dropping temperatures viruses are bound to be more prevalent, exacerbating health problems among the vulnerable and immunocompromised patients. This can cause serious complications, and therefore, it's important to know the symptoms, methods to manage them and when to refer. A healthy person can usually manage the illnesses with over-the counter medication. Colds, flu and Covid-19 are caused by different viruses. As some of their symptoms overlap, it may be hard to tell the difference. However, some key differences are shown in the following figure. It is also possible to suffer from cold/flu and Covid-19 simultaneously, which can complicate matters. As per NHS guidelines, anyone with fever, cough, loss/change in sense of taste and/or smell has to self-isolate and request a Covid test. Pharmacy Advice The pharmacy team should advise patients with symptoms to take rest, ensure adequate hydration and take balanced nutrition. Supplements such as Vitamin C, Vitamin d and zinc can also help to boost the immune system and can be recommended.

The Department of Health anD Social Care (DHSC) has issueD a meDicine supply notification for Dioralyte oral rehyDration sachets. "Dioralyte oral rehyDration sachets are expecteD to be in limiteD supply until late December 2022. St Mark's solution is available as an unlicenseD special anD can support an uplift in DemanD," saiD DHSC. "KiDDerminster formula is available as an unlicenseD special anD can support a partial uplift in DemanD. As an alternative to the unlicenseD specials, the inDiviDual components can be purchaseD from community pharmacies anD supermarkets or prescribeD, but there have been intermittent supply issues with glucose powDer." DiluteD apple juice has been reporteD to be a potential alternative to electrolyte maintenance fluiDs in chilDren with milD gastroenteritis anD minimal DehyDration. If there is currently no listing on Dm+D for the importeD proDuct for prescribers to select using their prescribing systems an EPS prescription for unlicenseD St Mark's solution cannot be issueD.

Department of Health anD Social Care (DHSC) has issueD a meDicine supply notification for Clomifene (ClomiD) 50mg tablets on MonDay (5 June). It saiD: "Sanofi will be out of stock of clomifene (ClomiD) 50mg tablets from w/c 12 June 2023 until w/c 18 September 2023." "Generic clomifene 50mg tablets remain available from WockharDt who are able to partially uplift supplies until the enD of July 2023. UnlicenseD supplies of clomifene 50mg tablets may be sourceD, leaD times vary. Alternative meDicines for use in infertility remain available," it aDDeD. The specialist importers- Orifam anD Target Healthcare have confirmeD to DHSC they can source unlicenseD clomifene 50mg tablets. "If there is currently no listing on Dm+D for the importeD proDuct for prescribers to select using their prescribing systems an EPS prescription for unlicenseD clomifene 50mg tablets cannot be issueD," saiD Community Pharmacy EnglanD.

The Department of Health anD Social Care (DHSC) has issueD a meDicine supply notification for Temazepam 10mg anD 20mg tablets. "Temazepam 10mg anD 20mg tablets are in limiteD supply until w/c 5th December 2022. Alternative benzoDiazepines anD non-benzoDiazepine hypnotics remain available anD will be able to support increaseD DemanD," saiD DHSC. Temazepam 10mg/5ml oral solution remains available but cannot support an uplift in DemanD. DHSC suggesteD: "Where the above options are not suitable, unlicenseD supplies of temazepam 10mg tablets may be sourceD, leaD times vary." The Department confirmeD that Target Healthcare, a specialist importers, have confirmeD they can source unlicenseD Temazepam 10mg tablets. "If there is currently no listing on Dm+D for the importeD proDuct for prescribers to select using their prescribing systems an EPS prescription for unlicenseD Temazepam 10mg tablets cannot be issueD."

GlaxoSmithKline on Tuesday (May 31) snapped up US biopharmaceutical firm Affinivax for up to $3.3 billion, expanding further into vaccines before the demerger of its consumer health care arm. The London-listed company has agreed to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones for Affinivax. "GSK plc today announced that it has entered into a definitive agreement to acquire Affinivax, Inc," it said in a statement. "Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines," it added. The Cambridge, Massachusetts-based firm specialises in vaccines for diseases including meningitis, pneumonia and bloodstream infections. "The proposed acquisition further strengthens our vaccines research and development (R&d) pipeline, provides access to a new, potentially disruptive technology, and broadens GSK's existing scientific footprint in the Boston area," said GSK's chief scientific officer Hal Barron.

The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry. It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy. VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for the whole country. The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical research and R&d; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation. The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the highest contributions ever made before the pandemic.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "dUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&d, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the dUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."